CONCLUSION: Persistent inflammation, defined simply and readily by FC>250 over two consecutive visits, was associated with a significantly higher risk and shorter time-to-occurrence of a composite outcome reflecting disease progression in asymptomatic infliximab-treated CD patients.

Full Text Link: https://libkey.io/34896644?utm_source=ibdwatch